title: Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
abstract: Cytogenetically normal acute myeloid leukemia (CN-AML) is the largest and most heterogeneous AML subgroup. It lacks sensitive and specific biomarkers. Emerging evidences have suggested that microRNAs are involved in the pathogenesis of various leukemias. This paper evaluated the association between microRNA expression and prognostic outcome for CN-AML, based on the RNA/microRNA sequencing data of CN-AML patients. High let-7a-2-3p expression and low miR-188-5p expression were identified to be significantly associated with longer overall survival (OS) and event free survival (EFS) for CN-AML, independently or in a combined way. Their prognostic values were further confirmed in European Leukemia Net (ELN) genetic categories. Also, in multivariable analysis with other known risk factors, high let-7a-2-3p and low miR-188-5p expression remained to be associated with longer OS and EFS. In addition, the prognostic value of these two microRNAs was confirmed in patients who received hematopoietic stem cell transplantation (HSCT). To gain more biological insights of the underlying mechanisms, we derived the genome-wide differential gene/microRNA signatures associated with the expression of let-7a-2-3p and miR-188-5p. Several common microRNA signatures indicating favorable outcome in previous studies were up-regulated in both high let-7a-2-3p expressers and low miR-188-5p expressers, including miR-135a, miR-335 and miR-125b and all members of miR-181 family. Additionally, common up-regulated genes included FOSB, IGJ, SNORD50A and ZNF502, and FOSB was a known favorable signature in AML. These common signatures further confirmed the underlying common mechanisms for these two microRNAs value as favorable prognostic biomarkers. We concluded that high let-7a-2-3p and low miR-188-5p expression could be potentially used as favorably prognostic biomarkers independently or in a combined way in CN-AML patients, whether they received HSCT or not.
authors: Medical Engineering Division, Hainan Branch, Chinese PLA General Hospital, Sanya, Hainan, China; Medical Engineering Support Center, Chinese PLA General Hospital, Beijing, China.
authors: Shi
authors: S
authors: Jinlong
authors: Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, China.
authors: Fu
authors: F
authors: Lin
authors: Department of Hematology, Chinese PLA General Hospital, Beijing, China.
authors: Li
authors: L
authors: Yonghui
authors: Department of Hematology, Chinese PLA General Hospital, Beijing, China.
authors: Yu
authors: Y
authors: Li
authors: Medical Engineering Support Center, Chinese PLA General Hospital, Beijing, China.
authors: Wang
authors: W
authors: Weidong
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D055815:Young Adult
chemical_list: C584093:MIRN188 microRNA, human; D035683:MicroRNAs; C487931:mirnlet7 microRNA, human
references: Blood. 1999 May 1;93(9):3074-80
references: 10216104
references: Br J Haematol. 2002 Aug;118(2):357-64
references: 12139719
references: Blood. 2002 Oct 15;100(8):2717-23
references: 12351377
references: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
references: 12434020
references: J Clin Oncol. 2004 Feb 15;22(4):624-33
references: 14726504
references: Cell. 2004 Jan 23;116(2):281-97
references: 14744438
references: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
references: 14973191
references: N Engl J Med. 2004 Apr 15;350(16):1617-28
references: 15084694
references: N Engl J Med. 2005 Jan 20;352(3):254-66
references: 15659725
references: Nature. 2005 Jun 9;435(7043):834-8
references: 15944708
references: Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
references: 16199517
references: Cancer Cell. 2006 Mar;9(3):189-98
references: 16530703
references: Blood. 2007 Jan 15;109(2):431-48
references: 16960150
references: Nat Rev Immunol. 2007 Jan;7(1):31-40
references: 17186029
references: Cancer Res. 2007 Jun 15;67(12):5699-707
references: 17575136
references: Blood. 2008 Mar 15;111(6):3183-9
references: 18187662
references: N Engl J Med. 2008 May 1;358(18):1919-28
references: 18450603
references: Br J Haematol. 2009 Feb;144(3):332-41
references: 19036090
references: Blood. 2009 Oct 1;114(14):2945-51
references: 19666866
references: Eur J Haematol. 2010 Jan 1;84(1):1-16
references: 19744129
references: Blood. 2009 Dec 17;114(26):5331-41
references: 19850741
references: J Cell Physiol. 2010 Apr;223(1):49-56
references: 20039279
references: Curr Drug Targets. 2010 Jul;11(7):801-11
references: 20370647
references: Blood. 2010 Aug 5;116(5):788-92
references: 20442368
references: Blood. 2010 Dec 16;116(25):5660-9
references: 20841507
references: Blood. 2011 Jan 27;117(4):1121-9
references: 21045193
references: J Clin Oncol. 2010 Dec 20;28(36):5257-64
references: 21079133
references: Oncogene. 2012 Jan 5;31(1):80-92
references: 21643017
references: Leukemia. 2012 Jan;26(1):1-12
references: 21701489
references: Cell. 2011 Sep 16;146(6):1016-28
references: 21925322
references: Oncogene. 2013 Jan 17;32(3):397-402
references: 22370638
references: Curr Opin Hematol. 2012 Jul;19(4):261-7
references: 22504525
references: Blood. 2012 Sep 6;120(10):2118-26
references: 22815426
references: Clin Cancer Res. 2013 Jan 15;19(2):327-35
references: 23209034
references: N Engl J Med. 2013 May 30;368(22):2059-74
references: 23634996
references: Cell Stem Cell. 2013 Jul 3;13(1):87-101
references: 23827711
references: Cancer Cell. 2013 Sep 9;24(3):365-78
references: 24029233
references: Leukemia. 2014 May;28(5):1022-32
references: 24270738
references: Leuk Res. 2014 Mar;38(3):402-10
references: 24484870
references: Cell Signal. 2014 Jul;26(7):1420-6
references: 24607788
references: FEBS Lett. 2014 Apr 2;588(7):1168-77
references: 24613927
references: Tumour Biol. 2014 Aug;35(8):8309-18
references: 24859837